Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GRAVITAS-301: Itacitinib in First-Line Acute GVHD
NCT03139604Phase 3Completed
- Sponsor
- Incyte
- Start
- Jul 2017
- Primary completion
- May 2019
- Modality
- Small Molecules
- Countries
- 19
01
Overview
A Phase 3 trial of itacitinib in Acute Graft-Versus-Host Disease (aGvHD), sponsored by Incyte. Started Jul 2017; status: completed.
02
Drugs
itacitinib
03
Conditions
Acute Graft-Versus-Host Disease (aGvHD)
Beyond the preview
Go deeper on NCT03139604.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03139604.